As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study, COMBI-APlus, which investigated whether an adapted pyrexia management algorithm could reduce serious pyrexia-related adverse outcomes in patients with BRAF V600 mutation-positive resected stage III melanoma.
Independent expert commentary is provided by Dr Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and with Adelaide Oncology and Haematology.
Please login below to download this issue (PDF)